Stonebridge Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Stonebridge Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100	Closed	-$1.02K	–	786
2023 Q3	$1.02K	Hold	100	–	–	﹤0.01%	858
2023 Q2	$753	Hold	100	–	–	﹤0.01%	872
2023 Q1	$885	Hold	100	–	–	﹤0.01%	867
2022 Q4	$912	Hold	100	–	–	﹤0.01%	870
2022 Q3	$1K	Hold	100	–	–	﹤0.01%	960
2022 Q2	$1K	Sell	100 -95	-49%	-$828	﹤0.01%	896
2022 Q1	$2K	Hold	195	–	–	﹤0.01%	928
2021 Q4	$2K	Hold	195	–	–	﹤0.01%	880
2021 Q3	$2K	Sell	195 -1,595	-89%	-$14.9K	﹤0.01%	847
2021 Q2	$19K	Buy	1,790 +895	+100%	+$9.47K	﹤0.01%	641
2021 Q1	$10K	Buy	+895	New	+$10.3K	﹤0.01%	641
2020 Q3	–	Sell	-695	Closed	-$9K	–	645
2020 Q2	$9K	Hold	695	–	–	﹤0.01%	508
2020 Q1	$6K	Hold	695	–	–	﹤0.01%	544
2019 Q4	$7K	Buy	695 +200	+40%	+$1.79K	﹤0.01%	607
2019 Q3	$3K	Hold	495	–	–	﹤0.01%	681
2019 Q2	$5K	Buy	+495	New	+$5.97K	﹤0.01%	682

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Stonebridge Capital Advisors's TEVA Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 100 shares — an estimated $1.02K sold.

Stonebridge Capital Advisors first reported a position in TEVA in Q2 2019 and held it in 16 quarters. The position peaked at $19K in Q2 2021. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 100 Teva Pharmaceuticals shares in Q4 2023, an estimated $1.02K.
Stonebridge Capital Advisors first reported a position in Teva Pharmaceuticals in Q2 2019 and held it in 16 quarters.
Stonebridge Capital Advisors's Teva Pharmaceuticals position peaked at $19K in Q2 2021.
447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.